blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3699181

EP3699181 - CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.01.2024
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  27.01.2023
FormerGrant of patent is intended
Status updated on  08.11.2022
FormerRequest for examination was made
Status updated on  21.10.2022
FormerGrant of patent is intended
Status updated on  09.08.2022
FormerRequest for examination was made
Status updated on  05.03.2021
FormerThe application has been published
Status updated on  24.07.2020
Most recent event   Tooltip27.06.2024Change - lapse in a contracting state
State(s) deleted from list of lapses: AL		published on 31.07.2024  [2024/31]
Applicant(s)For all designated states
Array Biopharma, Inc.
3200 Walnut Street
Boulder, CO 80301 / US
[2020/35]
Inventor(s)01 / ARRIGO, Alisha B.
Array Biopharma, Inc
3200 Walnut Street
Boulder, CO 80301 / US
02 / JUENGST, Derrick
Array Biopharma, Inc.
3200 Walnut Street
Boulder, CO 80301 / US
03 / SHAH, Khalid
12 Amberwood Circle
South San Francisco, CA 94080 / US
 [2020/35]
Representative(s)HGF
HGF Limited
4th Floor, 1 City Square
Leeds LS1 2ES / GB
[N/P]
Former [2023/09]HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
Former [2020/35]HGF
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date20169707.516.11.2015
[2020/35]
Priority number, dateUS201462080374P16.11.2014         Original published format: US 201462080374 P
US201562169545P01.06.2015         Original published format: US 201562169545 P
[2020/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3699181
Date:26.08.2020
Language:EN
[2020/35]
Type: B1 Patent specification 
No.:EP3699181
Date:01.03.2023
Language:EN
[2023/09]
Search report(s)(Supplementary) European search report - dispatched on:EP23.06.2020
ClassificationIPC:C07D487/04, A61K31/519, A61P35/00
[2020/35]
CPC:
A61K31/519 (EP,IL,KR,RU,US); C07D487/04 (EP,CN,IL,KR,RU,US); A61P25/04 (EP,IL);
A61P25/28 (EP,IL); A61P29/00 (EP,IL,RU); A61P31/04 (EP,IL);
A61P35/00 (EP,IL,RU); C12Q1/485 (CN,KR,US); C12Y207/10001 (EP,CN,KR,US);
C07B2200/13 (CN,IL,KR); G01N2333/91205 (CN,KR,US); G01N2800/52 (CN,KR,US);
Y02A50/30 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/14]
Former [2020/35]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA25.02.2021
ME25.02.2021
Validation statesMA25.02.2021
TitleGerman:KRISTALLINE FORM VON (S)-N-(5-((R)-2-(2,5-DIFLUORPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDIN-1-CARBOXAMID-SCHWEFELWASSERSTOFF[2020/35]
English:CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE[2020/35]
French:FORME CRISTALLINE D'HYDROGÉNOSULFATE DE (S)-N-(5-((R)-2-(2,5-DIFLUOROPHÉNYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE[2020/35]
Examination procedure25.02.2021Examination requested  [2021/14]
25.02.2021Date on which the examining division has become responsible
23.03.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
24.05.2021Amendment by applicant (claims and/or description)
10.08.2022Communication of intention to grant the patent
21.10.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.11.2022Fee for grant paid
04.11.2022Fee for publishing/printing paid
04.11.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP15808300.6  / EP3218380
Opposition(s)04.12.2023No opposition filed within time limit [2024/06]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
24.05.2021Request for further processing filed
24.05.2021Full payment received (date of receipt of payment)
Request granted
04.06.2021Decision despatched
Fees paidRenewal fee
15.04.2020Renewal fee patent year 03
15.04.2020Renewal fee patent year 04
15.04.2020Renewal fee patent year 05
13.11.2020Renewal fee patent year 06
21.10.2021Renewal fee patent year 07
13.10.2022Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipSM01.03.2023
[2024/31]
Former [2023/50]AL01.03.2023
SM01.03.2023
Former [2023/46]SM01.03.2023
Documents cited:Search[ID] WO2010048314  (ARRAY BIOPHARMA INC et al.)
 [A]   HARWOOD L M ET AL: "Experimental organic chemistry - Principles and practice", 1 January 1989, EXPERIMENTAL CHEMISTRY - ORGANIC CHEMISTRY AND REACTION,, PAGE(S) 127 - 132, ISBN: 978-0-632-02016-4, XP003025361
 [A]   VIPPAGUNTA S R ET AL: "Crystalline solids", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 48, no. 1, 16 May 2001 (2001-05-16), pages 3 - 26, XP008121199, ISSN: 0169-409X, [retrieved on 20010420], DOI: 10.1016/S0169-409X(01)00097-7

DOI:   http://dx.doi.org/10.1016/S0169-409X(01)00097-7
 [T]   PRODUCT QUALITY REVIEW(S): "APPLICATION NUMBER: 210861Orig1s000 211710Orig1s000", CENTER FOR DRUG EVALUATION AND RESEARCH, 15 October 2017 (2017-10-15), XP055703077, Retrieved from the Internet [retrieved on 20200609]
by applicantWO2006115452
 WO2006087538
 WO2008037477
 WO2008058126
 US2006094699
 WO2010033941
 WO2010048314
 WO2011006074
 WO2011146336
 US8513263
 US2013061211
 US2013057495
 US8299057
 US8399442
 US8937071
 US9006256
 US9035063
 US2014121239
 US2011053934
 US2011301157
 US2010324065
 US2009227556
 US2009130229
 US2009099167
 US2005209195
 WO2014184069
 WO2014072220
 WO2012053606
 WO2009017838
 WO2008031551
 WO2007136103
 WO2007087245
 WO2007057399
 WO2005051366
 WO2005044835
 WO2013059740
   PATAPOUTIAN, A. ET AL., CURRENT OPINION IN NEUROBIOLOGY, vol. 11, 2001, pages 272 - 280
   BRODEUR, G. M., NAT. REV. CANCER, vol. 3, 2003, pages 203 - 216
   DAVIDSON., B. ET AL., CLIN. CANCER RES., vol. 9, 2003, pages 2248 - 2259
   KRUETTGEN ET AL., BRAIN PATHOLOGY, vol. 16, 2006, pages 304 - 310
   DIONNE ET AL., CLIN. CANCER RES., vol. 4, no. 8, 1998, pages 1887 - 1898
   DANG ET AL., JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 21, no. 5, 2006, pages 850 - 858
   HU ET AL., CANCER GENETICS AND CYTOGENETICS, vol. 178, 2007, pages 1 - 10
   HANSEN ET AL., JOURNAL OF NEUROCHEMISTRY, vol. 103, 2007, pages 259 - 275
   BRZEZIANSKA ET AL., NEUROENDOCRINOLOGY LETTERS, vol. 28, no. 3, 2007, pages 221 - 229
   PEREZ-PINERA ET AL., MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 295, no. 1&2, 2007, pages 19 - 26
   MARCHETTI ET AL., HUMAN MUTATION, vol. 29, no. 5, 2008, pages 609 - 616
   BARDELLI, A., SCIENCE, vol. 300, 2003, pages 949
   NAKAGAWARA, A., CANCER LETTERS, vol. 169, 2001, pages 107 - 114
   MEYER, J. ET AL., LEUKEMIA, vol. 1-10, 2007, pages 2171 - 2180
   PIEROTTIA, M.A.GRECO A., CANCER LETTERS, vol. 232, 2006, pages 90 - 98
   ERIC ADRIAENSSENS, E. ET AL., CANCER RES, vol. 68, no. 2, 2008, pages 346 - 351
   WOOLF, C.J. ET AL., NEUROSCIENCE, vol. 62, 1994, pages 327 - 331
   ZAHN, P.K. ET AL., J. PAIN, vol. 5, 2004, pages 157 - 163
   MCMAHON, S. B. ET AL., NAT. MED., vol. 1, 1995, pages 774 - 780
   MA, Q. P.WOOLF, C. J., NEUROREPORT, vol. 8, 1997, pages 807 - 810
   SHELTON, D. L. ET AL., PAIN, vol. 116, 2005, pages 8 - 16
   DELAFOY, L. ET AL., PAIN, vol. 105, 2003, pages 489 - 497
   LAMB, K. ET AL., NEUROGASTROENTEROL. MOTIL., vol. 15, 2003, pages 355 - 361
   JAGGAR, S. I. ET AL., BR. J. ANAESTH., vol. 83, 1999, pages 442 - 448
   CHO, L. ET AL., BRAIN RESEARCH, vol. 749, 1997, pages 358
   CHANG-QI, L ET AL., MOLECULAR PAIN, vol. 4, no. 28, 2008, pages 27 - 11
   MATAYOSHI, S., J. PHYSIOL., vol. 569, 2005, pages 685 - 95
   THOMPSON, S.W., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 7714 - 18
   FREUND-MICHEL, VFROSSARD, N., PHARMACOLOGY & THERAPEUTICS, vol. 117, no. 1, 2008, pages 52 - 76
   HU VIVIAN Y, THE JOURNAL OF UROLOGY, vol. 173, no. 3, 2005, pages 1016 - 21
   DI MOLA, F. F, GUT, vol. 46, no. 5, 2000, pages 670 - 678
   DOU, Y.-C., ARCHIVES OF DERMATOLOGICAL RESEARCH, vol. 298, no. 1, 2006, pages 31 - 37
   RAYCHAUDHURI, S. P., JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 3, 2004, pages 812 - 819
   SOHRABJI, FARIDALEWIS, DANIELLE K., FRONTIERS IN NEUROENDOCRINOLOGY, vol. 27, no. 4, 2006, pages 404 - 414
   DE MELO-JORGE, M. ET AL., CELL HOST & MICROBE, vol. 1, no. 4, 2007, pages 251 - 261
   K. ASAUMI ET AL., BONE, vol. 26, no. 6, 2000, pages 625 - 633
   EXPERT OPIN. THER. PATENTS, vol. 19, no. 3, 2009
   REUTHER ET AL., MOL. CELL BIOL., vol. 20, 2000, pages 8655 - 8666
   J. MED.CHEM., vol. 55, no. 10, 2012, pages 4872 - 4876
   "The Handbook of Pharmaceutical Excipients", vol. 1-3, AMERICAN PHARMACEUTICAL ASSOCIATION, article "Revised and Expanded"
   VAISHNAVI ET AL., NATURE MED., vol. 1-2, 2013, pages 1469 - 1472
   TAIPALE ET AL., NATURE BIOTECH., vol. 31, 2013, pages 630 - 637
   SLEIJFER ET AL., EUR. J. CANCER, vol. 46, 2010, pages 72 - 83
   LINCH ET AL., CLIN. ONCOL., vol. 11, 2014, pages 187 - 202
   RUTKOWSKI ET AL., J. EUR. ACAD. DERMATOL. VENEREOL., vol. 25, 2011, pages 264 - 270
   VAISHNAVI ET AL., NATMED., vol. 19, 2013, pages 1469 - 72
   VAISHNAVI ET AL., CANCERDISCOV., vol. 5, 2015, pages 25 - 34
   WEISNER ET AL., NAT. COMM., vol. 5, 2014, pages 3116
   VAISHNAVI ET AL., CANCER DISCOV., vol. 5, 2015, pages 25 - 34
   DAVIES ET AL., PLOS ONE, vol. 8, 2013, pages e82236
   TAIPALE ET AL., NAT. BIOTECH., vol. 31, 2013, pages 630 - 637
   KEYSAR ET AL., MOL. ONCOL., vol. 7, 2013, pages 776 - 790
   BOUHANA ET AL., EORTC-NCI-AACR 26TH SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS, 2014
   STRANSKY ET AL., NATURE COMM., vol. 5, 2014, pages 4846
   GRECO ET AL., MOL. CELL. ENDOCRINOL., vol. 28, 2010, pages 321
   KIM ET AL., PLOS ONE, vol. 9, no. 3, 2014, pages e91940
   FERNANDEZ-CUESTA ET AL.: "Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets", AACR ANNUAL MEETING 2014, April 2014 (2014-04-01)
   ROSS ET AL., ONCOLOGIST, vol. 19, 2014, pages 235 - 242
   DOEBELE ET AL., J. CLIN. ONCOL., vol. 32, 2014, pages 5s
   JONES ET AL., NATURE GENETICS, vol. 45, 2013, pages 927 - 932
   WU ET AL., NATURE GENETICS, vol. 46, 2014, pages 444 - 450
   ZHENG ET AL.: "Anchored multiplex PCR for targeted next-generation sequencing", NATURE MED., 10 November 2014 (2014-11-10)
   CARIA ET AL., CANCER GENET. CYTOGENET., vol. 203, 2010, pages 21 - 29
   FRATTINI ET AL., NATURE GENET., vol. 45, 2013, pages 1141 - 1149
   MARTIN-ZANCA ET AL., NATURE, vol. 319, 1986, pages 743
   REUTHER ET AL., MOL. CELL. BIOL., vol. 20, 2000, pages 8655 - 8666
   TACCONELLI ET AL., CANCER CELL, vol. 6, 2004, pages 347
   WALCH ET AL., CLIN. EXP. METASTASIS, vol. 17, 1999, pages 307 - 314
   PAPATSORIS ET AL., EXPERT OPIN. INVEST. DRUGS, vol. 16, no. 3, 2007, pages 303 - 309
   VAN NOESEL ET AL., GENE, vol. 325, 2004, pages 1 - 15
   ZHANG ET AL., ONCOLOGY REPORTS, vol. 14, 2005, pages 161 - 171
   TRUZZI ET AL., J. INVEST. DERMATOL., vol. 128, no. 8, 2008, pages 2031
   KOLOKYTHAS ET AL., J. ORAL MAXILLOFACIAL SURGERY, vol. 68, no. 6, 2010, pages 1290 - 1295
   NI ET AL., ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol. 13, 2012, pages 1511
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.